Array says ARRY-614 data shows pronounced platelet effect in some patients

theflyonthewall.com

Array BioPharma announced updated clinical safety and efficacy data on ARRY‑614 in patients with myelodysplastic syndromes at the 2013 Annual Meeting of the American Society of Hematology. ARRY-614 is a potent inhibitor of p38/Tie2 with a mechanism of action distinct from drugs currently available to treat MDS. It is being studied in an ongoing dose-escalation trial in IPSS low/intermediate-1 risk MDS patients, representing a population of more than 100,000 patients in developed countries. The dose-escalation portion of the trial established the maximum tolerated dose, and subsequent expansion cohorts have been fully enrolled. Of patients currently evaluable for efficacy, 21% achieved a Hematologic Improvement. Of particular interest, 44% of platelet-transfusion dependent patients achieved Transfusion Reduction, and 31% achieved Transfusion Independence. Lower risk MDS patients with severe low platelet counts have a particularly poor prognosis. The most common treatment-related adverse events across all doses were rash, nausea, and atrial fibrillation. The majority of these events were mild or moderate in severity. "ARRY-614 was generally well tolerated in these lower-risk MDS patients and I am particularly encouraged with the platelet effects observed in patients with thrombocytopenia, including platelet transfusion independence," said Guillermo Garcia-Manero, M.D., Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

Rates

View Comments (0)